Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

KDA Group Not To Proceed with the Project to Distribute the ZRx Prescriber in the United States

V.KDA

(TheNewswire)

  

Thetford Mines / TheNewswire / August 28, 2018 - KDA Group Inc. (TSXV: KDA) (“KDA Group” or the “Corporation”) announced on June 1st, 2018 an agreement with ZoomMed Inc. (TSXV: ZMD) (“ZoomMed”) whereby KDA Group could have obtained the rights to distribute, under a non-exclusive license, the ZRx Prescriber developed by ZoomMed in the United States. The Corporation and ZoomMed had also announced that they were hoping to conclude a joint venture agreement in order to unite their expertise for the development and commercialization of the ZRx Prescriber in the US market.

Within the context of the agreement, KDA Group would have issued ZoomMed 10,000,000 common class A shares of its share capital (the “Common Shares”) at a deemed value of $1,720,000 CND, based on the average closing price of the Common Shares for the last 52 weeks to April 30th, 2018, being $ 0.172 CND per Common Share.

The agreement and share issuance were subject to obtaining all required approvals, including the final approval of the TSX Venture Exchange.

The Corporation announces that its board of directors has decided not to proceed with the project and to terminate the agreement between the Corporation and ZoomMed. Consequently, the Corporation will not issue the Common Shares to ZoomMed.

About KDA Group

KDA Group is a leading solution and service provider to the pharmaceutical market for the distribution of generic drugs and specialized solutions. Today, it is a respected name for quality and expertise among pharmacists. Its management team is guided by a vision of continuing to lead the way in Quebec while extending operations across Canada and internationally. Additional information on the Corporation is available at www.kdagroup.ca and on SEDAR at www.sedar.com.

 

CAUTION REGARDING FORWARD-LOOKING STATEMENTS

 

This press release from KDA Group contains forward-looking statements. Forward-looking statements are typically identified by the words assumption, goal, guidance, objective, outlook, strategy, target, and other similar expressions, or future or conditional verbs such as aim, anticipate, believe, predict, could, expect, intend, may, plan, seek, should, strive, and will. By their nature, forward-looking statements require us to make estimates and assumptions and express opinions based on current conditions and anticipated developments, as well as other factors that Management may deem appropriate under the circumstances. There is inherent uncertainty and significant risk in these estimates, assumptions, and opinions, particularly of a commercial, economic, and competitive nature, and they are therefore subject to change. KDA Group cannot guarantee that these estimates, assumptions, and opinions will prove to be accurate.

 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

 

INFORMATION

Marc Lemieux

Chief Executive Officer

514 622-7370

info@groupekda.ca

  

Copyright (c) 2018 TheNewswire - All rights reserved.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today